Abcam, ab286989, BMS-986020

Size: 25mg
MW 482.5 Da, Purity >98%. Potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist. LPA receptor is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a host of diverse biological functions, such as cell proliferation, platelet aggregation, smooth muscle contraction and others.
Key facts
CAS number:1257213-50-5,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:482.5 Da,
Molecular formula:C29H26N2O5,
PubChem:49792850,
Nature:Synthetic,
Solubility:DMSO (~20 mg/ml),
Biochemical name:Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]-,
Biological description:Potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist. LPA receptor is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a host of diverse biological functions, such as cell proliferation, platelet aggregation, smooth muscle contraction and others.,
Canonical smiles:CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O,
Isomeric smiles:CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O,
InChi:InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1,
InChiKey:GQBRZBHEPUQRPL-LJQANCHMSA-N,
IUPAC Name:1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called B2290 BMS-986020. B2290-25 is the same size as the 25 mg size of ab286989.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate long-term storage conditions--20°C, Storage information-This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EDG2 also known as LPA-1 LPAR1 or lysophosphatidic acid receptor 1 acts as a receptor for LPA (lysophosphatidic acid) a bioactive lipid mediator. This protein has a molecular mass of approximately 41 kDa. It is part of the G protein-coupled receptor (GPCR) family. EDG2 is mainly expressed in organs such as the brain heart and lungs. It plays an important role in cellular signal transduction by binding LPA which leads to various cellular responses.
Biological function summary
EDG2/LPA-1 influences several cellular processes including cell proliferation migration and survival. It does not function as part of a larger complex; instead it activates intracellular signaling cascades upon LPA binding. This activation leads to downstream effects that regulate processes like cytoskeletal reorganization and gene expression. Its influence extends to immune response modulation making it significant in understanding cellular behavior and communication.
Pathways
EDG2/LPA-1 is important in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K/AKT) signaling pathways. These pathways affect cell growth survival and metabolism showcasing the receptor's importance in cellular regulation. Through these pathways EDG2 interacts with multiple proteins including RAC1 a small GTPase involved in cytoskeletal organization and various kinase enzymes that facilitate signal transduction.
EDG2/LPA-1 has associations with cancer and fibrosis. In cancer the receptor influences tumor growth and metastasis due to its role in cell migration and proliferation. It connects to the matrix metalloproteinases (MMPs) in this context which degrade extracellular matrix components to facilitate cancer cell invasion. Additionally in fibrotic diseases EDG2's influence on fibroblast activity leads to tissue scarring and dysfunctional repair. Understanding these connections helps to explore therapeutic targets meant to modulate EDG2/LPA-1 activity in pathological conditions.